Info Onkologie

, Volume 15, Issue 5, pp 42–49 | Cite as

Lebermetastasen bei kolorektalen Tumoren — therapeutische Optionen

Eine Chance auf Heilung
zertifizierte fortbildung
First Online:

Zusammenfassung

Viele Patienten mit kolorektalen Tumoren entwickeln im Laufe ihrer Erkrankung Metastasen. Dabei gilt ein Hauptaugenmerk der Metastasierung in die Leber. Gerade wenn die Metastasierung in die Leber erfolgt, besteht noch eine gute Chance, die Erkrankung kurativ zu behandeln.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Van Cutsem E et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Douillard JY et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.PubMedCrossRefGoogle Scholar
  3. 3.
    Maughan TS et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Schmiegel W et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol. 2010;48(1):65–136.PubMedCrossRefGoogle Scholar
  5. 5.
    Stintzing S et al. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer. 2010;46(6):1026–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Scheele J et al. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Rougier P et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg. 1995;82(10):1397–400.PubMedCrossRefGoogle Scholar
  9. 9.
    Nordlinger B et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007; 43(14):2037–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Adam R et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Folprecht G et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study). 2009 Gastrointestinal Cancers symposium; J Clin Oncol. 2010;27:(suppl 4; abstr 296).Google Scholar
  12. 12.
    Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14(Suppl 2):ii13–6.PubMedGoogle Scholar
  13. 13.
    Van Cutsem E et al. European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Choti MA et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Fong Y et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938–46.PubMedGoogle Scholar
  16. 16.
    Portier G et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastasis: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Parks R et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metases: analysis of data from two continents. J Am Coll Surg. 2007;204(5):753–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Malafosse R et al. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12(7): 887–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Fong Y et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229(6):790–800.PubMedCrossRefGoogle Scholar
  20. 20.
    Elias D et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 2004;11(3):274–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Vauthey J-N et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13): 2065–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Benoit S et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45.CrossRefGoogle Scholar
  23. 23.
    Reddy SK et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007; 14(12): 3481–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Brouquet A et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29(8):1083–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Wicherts DA et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248(6):994–1005.PubMedCrossRefGoogle Scholar
  26. 26.
    Capussotti L et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93(8):1001–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Nishio H et al. Outcome following repeat liver resection for colorectal liver metasases. Eur J Surg Oncol. 2007;33(6):729–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Miller G et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007;205(2):231–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Mulier A et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Chirurgische Klinik und Poliklinik am Klinikum GroßhadernMünchenDeutschland

Personalised recommendations